• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy.

作者信息

Brem Elizabeth A, Shieh Kevin, Juarez Dennis, Buono Roberta, Jeyakumar Deepa, O'Brien Susan, Taylor Thomas H, Fruman David A

机构信息

Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Orange, CA.

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA.

出版信息

Blood Neoplasia. 2024 Aug 28;1(4):100036. doi: 10.1016/j.bneo.2024.100036. eCollection 2024 Dec.

DOI:10.1016/j.bneo.2024.100036
PMID:40552135
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12182841/
Abstract
摘要

相似文献

1
A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy.一项在急性髓系白血病（AML）和慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）中，将匹伐他汀添加到维奈克拉治疗的1期研究：一种基于机制的药物重新利用策略。
Blood Neoplasia. 2024 Aug 28;1(4):100036. doi: 10.1016/j.bneo.2024.100036. eCollection 2024 Dec.
2
Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG).接受维奈克拉方案治疗的慢性淋巴细胞白血病患者的肺炎：波兰成人白血病组（PALG）的真实世界分析
Cancers (Basel). 2024 Dec 13;16(24):4168. doi: 10.3390/cancers16244168.
3
Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation.依鲁替尼剂量调整对一线慢性淋巴细胞白血病/小淋巴细胞淋巴瘤总治疗时间的影响：一项使用目标试验模拟的真实世界分析。
Blood Neoplasia. 2024 Jun 10;1(3):100022. doi: 10.1016/j.bneo.2024.100022. eCollection 2024 Sep.
4
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.在前瞻性VenEx试验中，体外维奈托克敏感性可预测急性髓系白血病的临床反应。
Blood. 2025 Jan 23;145(4):409-421. doi: 10.1182/blood.2024024968.
5
Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中肿瘤溶解综合征的临床和经济负担：一项美国真实世界回顾性研究
J Manag Care Spec Pharm. 2022 Sep;28(9):1033-1045. doi: 10.18553/jmcp.2022.22075. Epub 2022 Jul 11.
6
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.伊布替尼联合维奈克拉治疗复发或难治性套细胞淋巴瘤（SYMPATICO）：一项多中心、随机、双盲、安慰剂对照的3期研究。
Lancet Oncol. 2025 Feb;26(2):200-213. doi: 10.1016/S1470-2045(24)00682-X.
7
Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome.在一名患有Brugada综合征的慢性淋巴细胞白血病患者中安全使用维奈克拉-奥妥珠单抗。
Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06457-0.
8
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.泽布替尼或伊布替尼用于复发或难治性慢性淋巴细胞白血病
N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.
9
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma.多发性骨髓瘤中维奈托克反应的预测因素及CDK7抑制的治疗潜力
Blood Neoplasia. 2024 Oct 14;1(4):100049. doi: 10.1016/j.bneo.2024.100049. eCollection 2024 Dec.
10
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States.美国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者存在2种或更多种淋巴细胞增多的真实世界特征、治疗模式及预后
Blood Neoplasia. 2024 Oct 14;2(1):100047. doi: 10.1016/j.bneo.2024.100047. eCollection 2025 Feb.

引用本文的文献

1
Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.靶向急性髓系白血病中的脂质代谢：生物学见解与治疗机遇
Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645-z.

本文引用的文献

1
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.他汀类药物诱导的线粒体预适应使多发性骨髓瘤细胞对 BCL2 和 MCL-1 抑制剂敏感。
Cancer Res Commun. 2023 Dec 8;3(12):2497-2509. doi: 10.1158/2767-9764.CRC-23-0350.
2
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.初治慢性淋巴细胞白血病的维奈托克联合治疗方案。
N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093.
3
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
初诊、未经治疗的 TP53 突变型急性髓系白血病的治疗结局：系统评价和荟萃分析。
J Hematol Oncol. 2023 Mar 6;16(1):19. doi: 10.1186/s13045-023-01417-5.
4
Targeting the Mevalonate Pathway in Cancer.靶向癌症的甲羟戊酸途径。
Trends Cancer. 2021 Jun;7(6):525-540. doi: 10.1016/j.trecan.2020.11.008. Epub 2021 Jan 6.
5
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.维奈托克联合 LDAC 方案用于不适合强化化疗的新诊断 AML：一项 3 期随机安慰剂对照试验。
Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856.
6
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
7
The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug repurposing.肿瘤学中美伐他汀类药物临床试验设计不佳可能是其失败的原因——药物再利用的教训。
Cancer Treat Rev. 2018 Sep;69:84-89. doi: 10.1016/j.ctrv.2018.06.010. Epub 2018 Jun 18.
8
Statins enhance efficacy of venetoclax in blood cancers.他汀类药物增强维奈托克在血液癌症中的疗效。
Sci Transl Med. 2018 Jun 13;10(445). doi: 10.1126/scitranslmed.aaq1240.
9
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).SWOG S0919复发/难治性队列研究报告：伊达比星和阿糖胞苷联合普伐他汀治疗急性髓系白血病（AML）的2期研究。
Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.
10
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.